Gilead's twice-yearly shot cut HIV infections by 96% in trial
September 12, 2024 at 09:29 AM EDT
The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|